COA & Testing
Independent third-party lab reports for the batches shown below. Only results the laboratory reported for that batch are shown. Look up any vial code or browse all products at batch reports.
10 mg
TRZ010-001Current batch — shipping now
- Purity
- 99.789%
- Measured peptide content
- 10.59 mg per vial
- Endotoxin test
- Pass
- Produced
- May 2026
View reportLaboratory copy ↗
30 mg
TRZ030-002Current batch — shipping now
- Purity
- 99.82%
- Measured peptide content
- 29.98 mg per vial
- Produced
- August 2026
View reportDownload PDF
Batches that did not pass testing
Published for transparency. These batches were never sold.
TRZ030-001Did not pass — not sold
- Purity
- 0%
- Measured peptide content
- 0 mg per vial
- Endotoxin test
- Pass
- Produced
- May 2026
- Reason
- Purity 0%, net content 0 mg, identity not confirmed (LC-MS)
View reportLaboratory copy ↗
TRZ010-002Did not pass — not sold
- Produced
- May 2026
- Reason
- Did not pass QC; details not published
Research Summary: The following information is provided for research context only.
Tirzepatide is a synthetic dual-receptor agonist peptide that binds two incretin receptors at once — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both receptors are widely studied in in-vitro metabolic and endocrine research, making this compound a useful reference tool for receptor-signaling studies.
In preclinical laboratory models, tirzepatide has been examined for receptor-binding affinity, downstream cAMP and insulinotropic signaling, and comparative agonist activity. Because it targets both the GIP and GLP-1 pathways simultaneously, it offers a model for characterizing how dual-receptor activation differs from single-receptor approaches.
Lyophilized Tirzepatide. The currently listed batch for each size has an independent third-party lab report in the COA & Testing tab. Each RR vial has a QR code linking to its batch’s independent COA.
Structure, CAS and molecular data, receptor pharmacology, storage and published literature: see our Tirzepatide research reference.
Reviews
There are no reviews yet.